newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell